Synthesis and evaluation of N
详细信息 查看全文
- 作者：Wu Du ; James P. Jewell ; Linus S. Lin ; Vincent J. Col ; rea ; Jing C. Xiao ; Julie Lao ; Chun-Pyn Shen ; Thomas J. Bateman ; Vijay B.G. Reddy ; Sookhee N. Ha ; Shrenik K. Shah ; Tung M. Fong ; Jeffrey J. Hale ; Wi
- 关键词：CB1R ; Inverse agonist ; Obesity ; Synthesis ; Metabolism
- 刊名：Bioorganic and Medicinal Chemistry Letters
- 出版年：2009
- 出版时间：1 September 2009
- 年：2009
- 卷：19
- 期：17
- 页码：5195-5199
- 全文大小：963 K
文摘
Obesity is a chronic medical condition that is affecting large population throughout the world. CB1 as a target for treatment of obesity has been under intensive studies. Taranabant was discovered and then developed by Merck as the 1st generation CB1R inverse agonist. Reported here is part of our effort on the 2nd generation of CB1R inverse agonist from the acyclic amide scaffold. We replaced the oxygen linker in taranabant with nitrogen and prepared a series of amino heterocyclic analogs through a divergent synthesis. Although in general, the amine linker gave reduced binding affinity, potent and selective CB1R inverse agonist was identified from the amino heterocycle series. Molecular modeling was applied to study the binding of the amino heterocycle series at CB1 binding site. The in vitro metabolism of representative members was studied and only trace glucuronidation was found. Thus, it suggests that the right hand side of the molecule may not be the appropriate site for glucuronidation.